☆ 4.5 Meeting Abstract

An analysis of treatment timing parameters for patients receiving neoadjuvant chemoradiation followed by surgery for esophageal adenocarcinoma: a National Cancer Data Base study

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2015)

Journal

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Volume 221, Issue 4, Pages E126-E126

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jamcollsurg.2015.08.236

Keywords

-

Categories

Surgery

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma

Felix Ho, Robert J. Torphy, Chloe Friedman, Stephen Leong, Sunnie Kim, Sachin Wani, Tracey Schefter, Christopher D. Scott, John D. Mitchell, Michael J. Weyant, Robert A. Meguid, Ana L. Gleisner, Karyn A. Goodman, Martin D. McCarter

Summary: In patients with esophageal and gastroesophageal junction adenocarcinoma, induction chemotherapy before neoadjuvant chemotherapy with concurrent radiotherapy was associated with significantly improved overall survival and higher pathological complete response rate. Furthermore, in patients diagnosed from 2013 to 2015, induction chemotherapy with neoadjuvant chemotherapy and concurrent radiotherapy was also linked to a higher odds of achieving pathological complete response.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Surgery

Value of Lymphadenectomy in Patients Receiving Neoadjuvant Therapy for Esophageal Adenocarcinoma

Siva Raja, Thomas W. Rice, Sudish C. Murthy, Usman Ahmad, Marie E. Semple, Eugene H. Blackstone, Hemant Ishwaran

Summary: This study demonstrates the importance of lymphadenectomy during esophagectomy for patients with adenocarcinoma of the esophagus and esophagogastric junction undergoing neoadjuvant therapy. Optimal range of nodes resected is associated with maximized survival, with a nonlinear relationship between lymph node resection and lifetime for different ypTNM cancer categories.

ANNALS OF SURGERY (2021)

Add to Collection

Article Oncology

The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma

D. J. Crull, M. C. H. Hogenes, R. Hoekstra, E. M. Hendriksen, M. J. van Det, E. A. Kouwenhoven

Summary: Adenocarcinoma subtype and grade did not impact overall survival (OS) or disease-free survival (DFS) in esophageal adenocarcinoma patients. However, combining a three-tier MTR with eighth AJCC staging improved the prognostic value for DFS after esophagectomy for neoadjuvant chemoradiotherapy-treated esophageal adenocarcinoma.

ANNALS OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Surgery

High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation Patients for Whom Surgery Should Not Be Delayed

Erin M. Bayley, Megan L. Ivy, Jitesh B. Shewale, Phillip S. Ge, Mara B. Antonoff, Ashleigh M. Francis, Wayne L. Hofstetter, Reza J. Mehran, Ravi Rajaram, David C. Rice, Jack A. Roth, Boris Sepesi, Ara A. Vaporciyan, Garrett L. Walsh, J. Jack Lee, Brian E. Louie, Stephen G. Swisher

Summary: Clinical predictors of pathological complete response are unreliable for identifying patients suitable for organ-sparing treatment after neoadjuvant chemoradiation in esophageal cancer. This study aimed to identify high-risk predictors of residual carcinoma that may exclude patients from a selective surgical approach.

ANNALS OF SURGERY (2023)

Add to Collection

Article Oncology

Clinicopathological Significance of Pathologic Complete Lymph Node Regression After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Po-Kuei Hsu, Yi-Chen Yeh, Ling- Chien, Chien-Sheng Huang, Han-Shui Hsu

Summary: Pathologic complete lymph node regression may be an indicator of sensitivity to neoadjuvant treatment and serves as a good prognostic factor in patients with esophageal squamous cell carcinoma.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival

Anne E. O'Shea, Phillip M. Kemp Bohan, Elizabeth L. Carpenter, Patrick M. McCarthy, Alexandra M. Adams, Robert C. Chick, Julia O. Bader, Robert W. Krell, George E. Peoples, Guy T. Clifton, Daniel W. Nelson, Timothy J. Vreeland

Summary: Downstaging after neoadjuvant therapies improves survival in patients with localized pancreatic adenocarcinoma. The addition of radiation therapy may increase the rate of downstaging without affecting overall oncologic outcomes.

ANNALS OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Surgery

Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma A Phase Ib/II Study

Darren Cowzer, Abraham Jing-Ching Wu, Smita Sihag, Henry S. Walch, Bernard J. Park, David R. Jones, Ping Gu, Steven B. Maron, Ryan Sugarman, Sree Bhavani Chalasani, Marina Shcherba, Marinela Capanu, Joanne F. Chou, Jennie K. Choe, Anton Nosov, Prasad S. Adusumilli, Randy Yeh, Laura H. Tang, David H. Ilson, Yelena Y. Janjigian, Daniela Molena, Geoffrey Y. Ku

Summary: The study aimed to determine the safety and efficacy of adding durvalumab to induction FOLFOX and preoperative chemotherapy in locally advanced esophageal adenocarcinoma. The results showed that adding durvalumab to induction FOLFOX and preoperative chemotherapy had a positive effect on improving pathologic complete response and prognosis.

ANNALS OF SURGERY (2023)

Add to Collection

Article Oncology

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma

Robyn D. Gartrell, Thomas Enzler, Pan S. Kim, Benjamin T. Fullerton, Ladan Fazlollahi, Andrew X. Chen, Hanna E. Minns, Subha Perni, Stuart P. Weisberg, Emanuelle M. Rizk, Samuel Wang, Eun Jeong Oh, Xinzheng Guo, Codruta Chiuzan, Gulam A. Manji, Susan E. Bates, John Chabot, Beth Schrope, Michael Kluger, Jean Emond, Raul Rabadan, Donna Farber, Helen E. Remotti, David P. Horowitz, Yvonne M. Saenger

Summary: Despite complete surgical resection and intense systemic therapies, patients with pancreatic ductal adenocarcinoma (PDAC) have a poor prognosis. Immunotherapies have almost uniformly failed in the treatment of PDAC. This study found that while chemoradiation therapy (CRT) can achieve high T cell densities in PDAC compared to melanoma, the phenotype and spatial organization of T cells may limit the benefit of T cell infiltration in this immunotherapy-resistant tumor.

ONCOIMMUNOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Staging Concordance and Guideline-Concordant Treatment for Esophageal Adenocarcinoma

Wilson Luiz Jr Jr da Costa, Xiangjun Gu, Farhood Farjah, Shawn S. Groth, Bryan M. Burt, Robert T. Ripley, Phillip W. Carrott, Nader N. Massarweh

Summary: Inaccurate clinical staging information for esophageal adenocarcinoma patients may lead to deviations from treatment guidelines, which should be a new focus for quality improvement efforts.

ANNALS OF THORACIC SURGERY (2022)

Add to Collection

Article Surgery

Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma

Rebecca A. Carr, Meier Hsu, Caitlin A. Harrington, Kay See Tan, Manjit S. Bains, Matthew J. Bott, David H. Ilson, James M. Isbell, Yelena Y. Janjigian, Steven B. Maron, Bernard J. Park, Valerie W. Rusch, Smita Sihag, Abraham J. Wu, David R. Jones, Geoffrey Y. Ku, Daniela Molena

Summary: This study compared the efficacy and safety of induction FOLFOX followed by PET-directed nCRT, induction CP followed by PET-directed nCRT, and nCRT with CP alone. The results showed that induction FOLFOX group had higher rates of pCR, near-pCR and 2-year DFS, suggesting that induction FOLFOX followed by PET-directed nCRT may be more effective than the other two methods.

ANNALS OF SURGERY (2023)

Add to Collection

Article Oncology

Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response

Dany Barrak, Anthony M. Villano, Nicole Villafane-Ferriol, Leah G. Stockton, Maureen Hill, Mengying Deng, Elizabeth A. Handorf, Sanjay S. Reddy

Summary: This study found that total neoadjuvant therapy (TNT) may be more likely to achieve a pathologic complete response (pCR) in the treatment of pancreatic adenocarcinoma compared to chemotherapy (CT) or chemoradiation (CRT), potentially improving overall survival (OS).

EJSO (2022)

Add to Collection

Article Oncology

Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma

Giuseppina Arbore, Luca Albarello, Gabriele Bucci, Marco Punta, Andrea Cossu, Lorella Fanti, Aurora Maurizio, Francesco Di Mauro, Vito Bilello, Gianluigi Arrigoni, Silvia Bonfiglio, Donatella Biancolini, Francesco Puccetti, Ugo Elmore, Luca Vago, Stefano Cascinu, Giovanni Tonon, Riccardo Rosati, Giulia Casorati, Paolo Dellabona

Summary: Current treatment for locally advanced esophageal adenocarcinoma involves neoadjuvant chemotherapy (nCT) before surgery, but response rates are low. This study examines the immune mechanisms involved in nCT response and identifies potential immune signatures that could be used for personalized treatment. The results show that patients with a complete response to nCT have increased immune response and proliferation, along with specific immune cell populations and cytokine profiles. These findings suggest that baseline tumor immunity plays a crucial role in the clinical activity of nCT and could be used to stratify patients for tailored treatments.

CANCER RESEARCH (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Using clinical and radiomic feature-based machine learning models to predict pathological complete response in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation

Jin Wang, Xiang Zhu, Jian Zeng, Cheng Liu, Wei Shen, Xiaojiang Sun, Qingren Lin, Jun Fang, Qixun Chen, Yongling Ji

Summary: This study aimed to build radiomic feature-based machine learning models to predict the pathological clinical response (pCR) of neoadjuvant chemoradiation therapy (nCRT) for esophageal squamous cell carcinoma (ESCC) patients. Results showed that both the radiomic model and the combination model had favorable performance in predicting ppCR and tpCR. This study contributes to treatment plan optimization.

EUROPEAN RADIOLOGY (2023)

Add to Collection

Article Oncology

Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma

Fereshteh Izadi, Benjamin P. Sharpe, Stella P. Breininger, Maria Secrier, Jane Gibson, Robert C. Walker, Saqib Rahman, Ginny Devonshire, Megan A. Lloyd, Zoe S. Walters, Rebecca C. Fitzgerald, Matthew J. J. Rose-Zerilli, Tim J. Underwood

Summary: Esophageal adenocarcinoma (EAC) patients receive pre-operative chemotherapy, but a significant portion do not respond to this treatment, exhibiting chromosomal instability and gene copy number alterations. Different genetic profiles, including mutations in the tumor suppressor NAV3, are associated with non-responders, presenting potential drug targets for alternative treatment pathways.

CANCERS (2021)

Add to Collection

Article Surgery

The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma

A. Justin Rucker, Vignesh Raman, Oliver K. Jawitz, Soraya L. Voigt, David H. Harpole, Thomas A. D'Amico, Betty C. Tong

Summary: This study aimed to determine whether adjuvant chemotherapy provides a survival benefit for high-risk patients with T2-4a, pathologically node-negative distal esophageal adenocarcinoma. The results showed that adjuvant chemotherapy, with or without radiation, did not demonstrate a significant survival benefit compared to no adjuvant therapy.

ANNALS OF SURGERY (2022)

Add to Collection

Meeting Abstract Oncology

Prognostic Models for Patients With Brain Metastases Treated With Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy

J. Hyder, S. M. Bentzen, A. Hanna, E. Choi, H. Boggs, Y. Kwok, S. J. Feigenberg, W. F. Regine, G. Woodworth, J. Barnholtz-Sloan, E. Weltman, P. W. Sperduto, M. P. Mehta

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)

Add to Collection

Meeting Abstract Oncology

Changes in neutrophil-to-lympocyte and platelet-to-lymphocyte ratios to predict survival and pathologic complete response in esophageal cancer patients who receive trimodality therapy.

Jalal Hyder, Drexell Boggs, Andrew Hanna, Mohan Suntharalingam, Michael David Chuong

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

What predicts early volumetric edema increase following stereotactic radiosurgery for brain metastases?

Andrew Hanna, D. Hunter Boggs, Young Kwok, Marc Simard, William F. Regine, Minesh Mehta

JOURNAL OF NEURO-ONCOLOGY (2016)

Add to Collection

Meeting Abstract Surgery

Does Your Team Matter? A Social Network Analysis of Enhanced Recovery after Surgery

Andrew Hanna, Michael C. Grant, Deborah B. Hobson, Andrew Benson, Susan L. Gearhart, Jonathan E. Efron, Jerry Stonemetz, Christopher Wu, Elizabeth C. Wick

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2016)

Add to Collection

Article Surgery

Dedicated Operating Room Teams and Clinical Outcomes in an Enhanced Recovery after Surgery Pathway for Colorectal Surgery

Michael C. Grant, Andrew Hanna, Andrew Benson, Deborah Hobson, Christopher L. Wu, Christina T. Yuan, Michael Rosen, Elizabeth C. Wick

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2018)

Add to Collection

Article Surgery

Laparoscopic Heller Myotomy vs Per Oral Endoscopic Myotomy: Patient-Reported Outcomes at a Single Institution

Andrew N. Hanna, Jashodeep Datta, Sara Ginzberg, Kevin Dasher, Gregory G. Ginsberg, Daniel T. Dempsey

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2018)

Add to Collection

Meeting Abstract Oncology

Application of a Survival-Predicting Nomogram Based Primarily on Whole-Brain Radiation Therapy-Treated Patients With Brain Metastases Yields Significant Underestimates for Radiosurgery-Treated Patients

E. Choi, A. A. Diamond, A. Hanna, H. Boggs, S. J. Feigenberg, Y. Kwok, J. M. Simard, J. Barnholtz-Sloan, M. P. Mehta

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)

Add to Collection

Article Surgery

Hiatal Hernia after Esophagectomy: An Underappreciated Complication?

Andrew N. Hanna, Isabella Guajardo, Noel Williams, John Kucharczuk, Daniel T. Dempsey

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2020)

Add to Collection

Article Oncology

Oncogenic KIT Modulates Type I IFN-Mediated Antitumor Immunity in GIST

Mengyuan Liu, Mark S. Etherington, Andrew Hanna, Benjamin D. Medina, Gerardo A. Vitiello, Timothy G. Bowler, Nesteene J. Param, Lillian Levin, Ferdinand Rossi, Ronald P. DeMatteo

Summary: Type I IFNs play a role in tumor immunogenicity and response to therapy; oncogene signaling, like KIT, affects IFN-I signaling and regulates tumor MHC class I expression; enhancing the type I IFN response can partially compensate for the immunosuppressive effects of KIT inhibition in GIST.

CANCER IMMUNOLOGY RESEARCH (2021)

Add to Collection

Article Oncology

Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome

Andrew Hanna, Caroline Kim-Kiselak, Rebecca Tang, David C. Metz, Zhaohai Yang, Ronald DeMatteo, Douglas L. Fraker, Robert E. Roses

Summary: This study identified predictors of outcome in GNET patients, finding that tumor size and grade can predict recurrence and survival. Patients with small, low-grade type III GNETs have minimal risk of progression and higher survival rates.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Editorial Material Oncology

ASO Visual Abstract: Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome

Andrew Hanna, Caroline Kim-Kiselak, Rebecca Tang, David C. Metz, Zhaohai Yang, Ronald DeMatteo, Douglas L. Fraker, Robert E. Roses

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Editorial Material Oncology

ASO Author Reflections: How Important is Type in the Management of Gastric Neuroendocrine Tumors?

Andrew Hanna, Robert E. Roses

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Tyrosine Kinase Inhibition Alters Intratumoral CD8+ T-cell Subtype Composition and Activity

Andrew D. Tieniber, Andrew N. Hanna, Benjamin D. Medina, Gerardo A. Vitiello, Mark S. Etherington, Mengyuan Liu, Kevin J. Do, Ferdinando Rossi, Ronald P. DeMatteo

Summary: Imatinib treatment reduces effector CD8(+) T cells and increases naïve CD8(+) T cells in GIST, impacting tumor chemokine production, T-cell recruitment, and signaling pathways. Combining IL15 superagonist with imatinib restores effector CD8(+) T cell function, leading to greater tumor destruction and improved outcomes, suggesting potential for T-cell therapy during TKI and/or ICB administration.

CANCER IMMUNOLOGY RESEARCH (2022)

Add to Collection

Article Oncology

Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in PDGFRA D842V-Mutant Gastrointestinal Stromal Tumor

Ferdinand Rossi, Mengyuan Liu, Andrew Tieniber, Mark S. Etherington, Andrew Hanna, Gerardo A. Vitiello, Nesteene J. Param, Kevin Do, Laura Wang, Cristina R. Antonescu, Shan Zeng, Jennifer Q. Zhang, Ronald P. DeMatteo

Summary: This study created an in vivo model of PDGFRA D842V-mutant gastrointestinal stromal tumor (GIST) and identified MYLK upregulation as a novel mechanism of tumor persistence following avapritinib therapy. Inhibition of MYLK can enhance the antitumor effects of avapritinib, providing a potential strategy for reducing side effects by lowering the dose.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.